0A4D fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March 2017 and is headquartered in La Jolla, CA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
0A4D has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company